Selected article for: "care point and new approach"

Author: Gal, Micaela; Francis, Nicholas A.; Hood, Kerenza; Villacian, Jorge; Goossens, Herman; Watkins, Angela; Butler, Christopher C.
Title: Matching diagnostics development to clinical need: Target product profile development for a point of care test for community-acquired lower respiratory tract infection
  • Cord-id: m8h12gh0
  • Document date: 2018_8_1
  • ID: m8h12gh0
    Snippet: BACKGROUND: Point of care tests (POCTs) are increasingly being promoted for guiding the primary medical care of community acquired lower respiratory tract infections (CA-LRTI). POCT development has seldom been guided by explicitly identified clinical need and requirements of the intended users. Approaches for identifying POCT priorities and developing target product profiles (TPPs) for POCTs in primary medical care are not well developed, and there is no published TPP for a CA-LRTI POCT aimed at
    Document: BACKGROUND: Point of care tests (POCTs) are increasingly being promoted for guiding the primary medical care of community acquired lower respiratory tract infections (CA-LRTI). POCT development has seldom been guided by explicitly identified clinical need and requirements of the intended users. Approaches for identifying POCT priorities and developing target product profiles (TPPs) for POCTs in primary medical care are not well developed, and there is no published TPP for a CA-LRTI POCT aimed at developed countries. METHODS: We conducted workshops with expert stakeholders and a survey with primary care clinicians to produce a target product profile (TPP) to guide the development of a clinically relevant and technologically feasible POCT for CA-LRTI. RESULTS: Participants with clinical, academic, industrial, technological and basic scientific backgrounds contributed to four expert workshops, and 45 practicing primary care clinicians responded to an online survey and prioritised community-acquired pneumonia (CAP) as the CA-LRTI where a new POCT was most urgently needed. Consensus was reached on a TPP document that included information on the intended niche in the clinical pathway in primary medical care; diagnostic product specification (intended use statement and test concept), and minimum and ideal user specifications. Clinicians minimum requirements of a CA-LRTI POCT included the use of minimally invasive samples, a result in less than 30 minutes, no more than a single preparation step, minimum operational requirements, and detection of common respiratory pathogens and their resistance to commonly prescribed antibiotics. CONCLUSIONS: This multidisciplinary, multistage partnership approach generated a clinically-driven TPP for guiding the development of a new POCT, and this approach as well as the TPP itself may be useful to others developing a new POCT.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active infection: 1, 2, 3
    • absence presence and acute exacerbation: 1, 2
    • absence presence and acute illness: 1, 2, 3, 4, 5, 6
    • absence presence and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • absence presence and acute onset: 1, 2
    • accordingly critical and acute infection: 1
    • acquired pneumonia and active infection: 1, 2
    • acquired pneumonia and acute cough: 1, 2, 3, 4, 5
    • acquired pneumonia and acute cough patient: 1, 2
    • acquired pneumonia and acute cough usually: 1
    • acquired pneumonia and acute exacerbation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acquired pneumonia and acute illness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acquired pneumonia and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acquired pneumonia and acute infiltrate: 1
    • acquired pneumonia and acute onset: 1, 2, 3, 4, 5, 6, 7
    • acquired pneumonia and acute viral respiratory tract infection: 1
    • active infection and acute illness: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection and acute onset: 1